FDA Panel Endorses Capivasertib for PTEN-Deficient Prostate Cancer
FDA Panel Endorses Capivasertib Use in Prostate Cancer | MedPage Today
Patient-Friendly Overview of the CAPItello-281 Trial and May 1, 2026 ODAC Approval
May 1, 2026
Bottom Line Up Front (BLUF)
On April 30, 2026, the FDA's independent Oncologic Drugs Advisory Committee voted 7-1 to recommend approval of capivasertib (Truqap), a targeted drug that blocks a specific growth pathway, combined with abiraterone and prednisone for men with metastatic hormone-sensitive prostate cancer that carries a PTEN gene deficiency—a marker of more aggressive disease. The CAPItello-281 trial showed the combination delayed cancer progression by a median of 7.5 months. While the FDA is not required to follow the committee's recommendation, it typically does.
What Happened and Why It Matters
On April 30, 2026, the FDA's Oncologic Drugs Advisory Committee (ODAC)—a group of independent medical experts who review evidence for the agency—voted to recommend that the FDA approve a new treatment combination for a specific subset of men with advanced prostate cancer. The drug is capivasertib (brand name Truqap), and it would be used together with abiraterone (Zytiga) and prednisone in men whose cancers have lost a tumor-suppressor gene called PTEN.
This approval matters because PTEN loss is associated with more aggressive, harder-to-treat disease. Approximately 25% of men with metastatic hormone-sensitive prostate cancer have PTEN-deficient tumors—meaning roughly one in four men with this stage of disease. For these men, standard treatments don't work as well, and new options are needed.
Understanding PTEN: Why It Matters
To understand why capivasertib is important, it helps to know what PTEN is and what happens when it's lost.
What is PTEN?
PTEN is a gene that normally acts as a "brake" on cell growth. It produces a protein that suppresses a molecular pathway called the PI3K/AKT pathway, which drives cell division and survival. When PTEN is working normally, cancer cells have trouble growing.
When PTEN is deleted or lost—as detected by immunohistochemistry (IHC) in tumor tissue—that brake is removed. The PI3K/AKT pathway becomes hyperactive, giving cancer cells an independent signal to grow that doesn't depend on testosterone or the androgen receptor. This is why men with PTEN loss don't respond as well to standard hormone-blocking drugs like abiraterone.
- Associated with faster progression to castration-resistant prostate cancer (CRPC)
- Linked to significantly shorter overall survival
- Predicts higher biochemical recurrence risk and more aggressive disease grade
- Occurs in approximately 25% of men with metastatic hormone-sensitive prostate cancer
This molecular understanding is why PTEN status should inform treatment decisions. Men with PTEN-deficient tumors need drugs that target the specific pathways driving their cancer, not just hormone-blocking strategies.
The CAPItello-281 Trial: Design and Key Results
The phase III CAPItello-281 trial tested whether adding capivasertib to standard abiraterone therapy could help men with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
Trial Design
The trial was randomized and double-blind, meaning:
- 1,012 men with newly diagnosed metastatic prostate cancer and confirmed PTEN deficiency were randomly assigned to one of two groups
- One group received capivasertib (400 mg twice daily on days 1–4 of each 28-day cycle) plus abiraterone, prednisone, and androgen deprivation therapy (ADT)
- The other group received placebo plus the same hormone therapies
- Neither patients nor physicians knew who was receiving capivasertib
- PTEN deficiency was confirmed by a central laboratory using immunohistochemistry with a cutoff of ≥90% of tumor cells showing no PTEN staining
Primary Results: Radiographic Progression-Free Survival
Placebo + abiraterone group: Median rPFS of 25.7 months
Statistical significance: P = 0.034 (clinically and statistically significant)
What this means: Men taking capivasertib delayed cancer progression (as shown on CT or bone scans) by approximately 7.5 months on average compared to those on placebo.
Patient-Reported Outcomes: Quality of Life
An important concern with combination therapy is whether side effects significantly harm patients' quality of life. The trial included detailed patient-reported outcome (PRO) assessments:
Quality of Life Findings
Good news: Overall quality of life and functional well-being were similar between the capivasertib and placebo groups over the course of treatment.
Early disruption: Men on capivasertib did report early, transient declines in physical well-being—meaning the side effects hit hardest at the start but didn't persist throughout treatment.
Overall Survival: Immature But Promising
The trial showed a trend favoring the capivasertib arm for overall survival (OS), but overall survival data remain immature—meaning not enough men have died yet to draw firm conclusions. Notably, at interim analysis, the hazard ratio was 0.90 (95% CI: 0.71–1.15), numerically favoring capivasertib, though the confidence interval includes 1.0. This will be updated as the trial continues to follow patients.
What is Capivasertib?
Capivasertib is a selective AKT inhibitor—a targeted drug that blocks a specific protein in the PI3K/AKT growth pathway. When PTEN is lost, this pathway becomes overactive. By blocking AKT (a protein downstream of PI3K), capivasertib cuts off a major growth signal that standard hormone therapies cannot stop.
The drug was first approved by the FDA in 2023 for advanced or metastatic breast cancer in patients whose tumors carry alterations in PIK3CA, AKT1, or PTEN. This new application extends it to prostate cancer—a different disease context, but one where the same pathway is dysregulated.
Capivasertib is given intermittently (days 1–4 of each 28-day cycle at 400 mg twice daily), not continuously. This schedule is thought to help reduce toxicity while maintaining efficacy.
Side Effects and Tolerability Concerns
The committee acknowledged that capivasertib adds toxicity to abiraterone therapy. FDA staff noted concerns about the added burden, and one panelist voted no, citing the "magnitude and duration of toxicity" relative to the benefit.
Common Side Effects of Capivasertib
- Diarrhea (most common, often on-target for AKT inhibitors)
- Rash and skin reactions (hyperkeratosis, dry skin)
- Hyperglycemia (elevated blood sugar)
- Diabetes ketoacidosis (rare but serious; requires monitoring)
Important context: During the ODAC discussion, Dr. Neil Vasan of NYU Langone Health noted that oncologists believe these toxicities are "manageable" and "tailored individually for each patient" through dose adjustments, supportive care, and careful selection of which patients receive the drug. This is a key point: capivasertib is not meant for all men with advanced prostate cancer—only those with PTEN-deficient tumors who are thought able to tolerate the side effects.
The fact that patient-reported quality of life remained stable despite these side effects suggests that active management can preserve overall well-being, even as individual toxicities occur.
What the Panel Decided and Why
The vote was 7 in favor, 1 against, and 1 abstention. This strong endorsement reflects the panel's judgment that the benefits outweigh the risks—but the minority views are important to understand.
Arguments in Favor
Dr. William Gradishar (Northwestern Feinberg School of Medicine): "My impression is that the 7-plus months is meaningful…as physicians become more acquainted with the drug, and the management for the right patients, it could have a meaningful outcome."
Dr. Toni Choueiri (Dana-Farber Cancer Institute): Emphasized that men with 99–100% PTEN loss represent a particularly aggressive subgroup. He asked, "How can they receive this targeted treatment if we don't approve it?" He also noted that the trial is "statistically significant" and "absolutely biologically plausible"—meaning the mechanism makes scientific sense.
The Dissenting Vote
Dr. Brian Rini (Vanderbilt University Medical Center) voted no, saying he was "swayed mostly by what I perceived as a relatively marginal benefit, and the magnitude and duration of toxicity." This is a legitimate concern: is 7.5 months of delayed progression worth the added toxicity for every patient? The answer may differ for each individual.
FDA Staff Concerns
Notably, FDA staff reviewers expressed skepticism in their briefing documents before the meeting, noting:
- Concerns about added toxicity with the combination
- Suggestion that the PFS benefit may not be "clinically meaningful"
- Observation that the 7.5-month improvement is smaller than improvements seen in prior approvals for mHSPC (e.g., abiraterone and enzalutamide added 5–10 months at approval)
- Statement that "a statistically significant improvement in overall survival may be needed to support a clinically meaningful treatment effect"
This disagreement between staff and the advisory committee is not unusual. The committee weighed the totality of evidence—including the mechanism of action, the patient population's poor prognosis, quality-of-life data, and the unmet need for PTEN-deficient disease—and concluded the benefit justifies approval. The FDA, however, is not required to follow the committee's vote and will make its own decision.
What Happens Next?
The advisory committee's vote is a strong recommendation but not a decision. The FDA's Oncologic Drugs Office will now review all the data—including the committee's discussion and votes—and decide whether to approve capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer. Historically, the FDA follows its advisory committees' recommendations in the majority of cases, though not always.
If approved, capivasertib would become available as a first-in-class targeted therapy for PTEN-deficient mHSPC—meaning it would be the first drug specifically designed to target this pathway in this population.
If Approved: Patient Eligibility Considerations
Not all men with advanced prostate cancer would be candidates. The treatment would be reserved for:
- Men with metastatic hormone-sensitive prostate cancer (not CRPC)
- With confirmed PTEN deficiency (≥90% loss by immunohistochemistry)
- Adequate kidney and liver function (for drug metabolism)
- Ability to tolerate and manage the side effects (diarrhea, rash, glucose monitoring)
Implications for Men with Prostate Cancer
Why PTEN Testing Matters
If capivasertib is approved, knowing your tumor's PTEN status will be increasingly important. While some major academic centers already perform PTEN testing, it is not yet standard of care nationwide. Patients diagnosed with metastatic prostate cancer should ask their oncologist:
- "Has my tumor been tested for PTEN status?"
- "If not, can we perform that test?" (It requires tissue from a biopsy or surgical sample, not blood)
- "What does my PTEN status mean for my treatment options?"
Treatment Decision-Making
If you have PTEN-deficient metastatic prostate cancer, the approval of capivasertib adds a new option to discuss with your oncology team. However, treatment decisions should be individualized. Factors to consider include:
- Your overall health and kidney/liver function
- Ability to tolerate diarrhea, rash, and blood sugar changes
- Whether 7.5 months of delayed progression aligns with your goals and life expectancy
- Availability of capivasertib at your treatment center
- Your insurance coverage and out-of-pocket costs
The Bigger Picture: Precision Medicine
This approval represents a shift toward precision medicine in prostate cancer—moving away from one-size-fits-all hormone therapy toward treatments designed for specific molecular subtypes. Men with PTEN loss have biologically distinct disease that responds differently to standard drugs. Targeted therapy for their specific alteration makes scientific sense.
As Dr. Choueiri noted, this targeted approach opens the door to treating other molecularly-defined subgroups. The research pipeline includes trials of other PI3K/AKT inhibitors, MAPK pathway inhibitors, and combination strategies tailored to individual tumor genetics.
Questions to Discuss with Your Oncologist
- Has my tumor been tested for PTEN status? If not, can we arrange that test?
- If I have PTEN deficiency, what are my treatment options?
- If capivasertib becomes approved, am I a candidate?
- What are the specific side effects I should watch for, and how would they be managed?
- Are there clinical trials enrolling patients with PTEN-deficient disease?
Summary: What You Need to Know
The approval of capivasertib—if the FDA follows the committee's recommendation—signals growing recognition that one treatment does not fit all in advanced prostate cancer. Molecular testing, precision medicine, and tailored therapy are becoming standard. If you or a loved one is living with metastatic prostate cancer, ensure your team knows your tumor's molecular profile and uses that information to guide the best possible treatment plan.
Sources and References
Comments
Post a Comment